| |
original article |
Date |
Title |
Authors All Authors |
| 1 |
[GO] |
2025―Jul―01 |
FDA-approved drugs as potential covalent inhibitors of key SARS-CoV-2 proteins: an in silico approach |
MURAT SERİLMEZ, ANWAR ABUELRUB, İSMAİL EROL, SERDAR DURDAĞI |
| 2 |
[GO] |
2024―Aug―25 |
Anatolian medicinal plants as potential antiviral agents: bridging traditional knowledge and modern science in the fight against COVID-19 and related viral infections |
ENGİN TİLKAT, ISRAT JAHAN, AYŞE HOŞER, ALEVCAN KAPLAN, OĞUZHAN ÖZDEMİR, AHMET ONAY |
| 3 |
[GO] |
2024―Jan―04 |
CompCorona: A web application for comparative transcriptome analyses of
coronaviruses reveals SARS-CoV-2-specific host response |
RANA SALİHOĞLU, FATİH SARAÇOĞLU, MUSTAFA SİBAİ, TALİP ZENGİN, BAŞAK ABAK MASUD, ONUR KARASOY, Tuğba Önal Süzek |
| 4 |
[GO] |
2022―Aug―24 |
Development a novel multi-epitope DNA vaccine against human SARS coronavirus-2: an immunoinformatics designing study |
AFSHIN SAMIMI NEMATI, SAKO MIRZAIE, MOHAMMAD REZA MASOUMIAN, FATEMEH SHEIKHI, MOSTAFA JAMALAN |
| 5 |
[GO] |
2022―May―18 |
Adoptive T-cell therapies to overcome T cell-dependent immune dysregulations in COVID-19 |
SEVGİ KALKANLI TAŞ, MERVE SAİDE UZUNOĞLU, AYLİN SEHER UZUNOĞLU, DUYGU KIRKIK, DERYA ALTUNKANAT, NEVİN KALKANLI |
| 6 |
[GO] |
2021―Dec―22 |
Adoptive T-cell therapies to overcome T cell-dependent immune dysregulations in COVID-19 |
|
| 7 |
[GO] |
2021―Aug―09 |
Binary-QSAR guided virtual screening of FDA approved drugs and compounds in clinical investigation against SARS-CoV-2 main protease |
|
| 8 |
[GO] |
2021―Aug―09 |
The current state of validated small molecules inhibiting SARS-CoV-2 non-structural proteins |
|
| 9 |
[GO] |
2021―Aug―02 |
Neuropathy in COVID-19 associated with dysbiosis-related inflammation |
|
| 10 |
[GO] |
2021―Aug―02 |
CoronaVac (Sinovac) COVID-19 vaccine-induced molecular changes in healthy human serum by infrared spectroscopy coupled with chemometrics |
|
| 11 |
[GO] |
2021―Aug―02 |
Cannabinoids for SARS-CoV-2 and is there evidence of their therapeutic efficacy? |
|
| 12 |
[GO] |
2021―Aug―02 |
Host Variations in SARS-CoV-2 Infection |
|
| 13 |
[GO] |
2021―Aug―02 |
ß-Carboline alkaloids induce structural plasticity and inhibition of SARS-CoV-2 nsp3 macrodomain more potently than remdesivir metabolite GS-441524: Computational approach |
|
| 14 |
[GO] |
2021―Aug―02 |
Genomic Chronicle Of SARS-COV-2: A Mutational Analysis with Over 1 million Genome Sequences |
|
| 15 |
[GO] |
2021―Jul―29 |
An update comprehensive review on the status of COVID-19: vaccines, drugs, variants and neurological symptoms |
|
| 16 |
[GO] |
2021―Jul―20 |
Novel approaches for COVID-19 diagnosis and treatment: A Nonsystematic Review |
|
| 17 |
[GO] |
2021―Jul―02 |
Treatment of COVID-19 Patients with Quercetin in Combination with Vitamin C and Bromelain: A Prospective, Single - Centre, Randomized, Controlled Trial |
|
| 18 |
[GO] |
2021―Jun―14 |
Targeting CoV-2 Spike RBD and ACE-2 Interaction with Flavonoids of Anatolian Propolis by in silico and in vitro Studies in Terms of Possible COVID-19 Therapeutics |
|
| 19 |
[GO] |
2021―Jun―07 |
Pathogenesis and Treatment of Cytokine Storm in COVID-19 |
|
| 20 |
[GO] |
2021―Jun―07 |
Determination of the interaction between the receptor binding domain of 2019-nCoV spike protein, TMPRSS2, cathepsin B and cathepsin L and glycosidic and aglycon forms of some flavonols |
|
| 21 |
[GO] |
2021―May―14 |
The potential use of Drosophila as an in vivo model organism for COVID-19-related research: A review |
|
| 22 |
[GO] |
2021―May―09 |
In silico drug repositioning against human NRP1 to block SARS-CoV-2 host entry |
|
| 23 |
[GO] |
2021―Jan―03 |
Current mutatome of SARS-CoV-2 in Turkey reveals mutations of interest |
|
| 24 |
[GO] |
2020―Jun―12 |
SARS-CoV-2 Isolation and Propagation from Turkish COVID-19 patients |
|
| 25 |
[GO] |
2020―Jun―12 |
Interaction of certain monoterpenoid hydrocarbons with the receptor-binding domain of 2019 novel coronavirus (2019-nCoV), transmembrane serine protease 2 (TMPRSS2), cathepsin B, and cathepsin L (CatB/L) and their pharmacokinetic properties |
|
| 26 |
[GO] |
2020―Jun―12 |
An updated analysis of variations in SARS-CoV-2 genome |
|
| 27 |
[GO] |
2020―Jun―12 |
Integration of transcriptomic profile of SARS-CoV-2 infected normal human bronchial epithelial cells with metabolic and protein-protein interaction networks |
|
| 28 |
[GO] |
2020―Jun―12 |
SARS-CoV-2 neutralizing antibody development strategies |
|
| 29 |
[GO] |
2020―Jun―09 |
An Insight into the Epitope-Based Peptide Vaccine Design Strategy and Studies Against COVID-19 |
|
| 30 |
[GO] |
2020―Jun―09 |
Gut-lung axis and dysbiosis in COVID-19 |
|
| 31 |
[GO] |
2020―Jun―09 |
Potentials of Plant-based Substance to Inhabit and Probable Cure for the COVID-19 |
|
| 32 |
[GO] |
2020―Jun―09 |
Phylogenetic Analysis of SARS-CoV-2 Genomes in Turkey |
|
| 33 |
[GO] |
2020―Jun―09 |
Identification of the nucleotide substitutions in 62 SARS-CoV-2 sequences from Turkey |
|
| 34 |
[GO] |
2020―Jun―09 |
Virtual drug repurposing study against SARS-CoV-2 TMPRSS2 target |
|
| 35 |
[GO] |
2020―Jun―09 |
Biosafety and Biosecurity Approaches to Restrain/Contain and Counter SARS-CoV-2/COVID-19 Pandemic: A Rapid-Review |
|
| 36 |
[GO] |
2020―May―18 |
COVID-19: Current Knowledge, Disease Potential, Prevention and Clinical Advances |
|
| 37 |
[GO] |
2020―May―05 |
Mesenchymal stem cell derived extracellular vesicles: promising immunomodulators against autoimmune, autoinflammatory disorders and SARS-CoV-2 infection |
|
